TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: all of below~* adults aged 18-70 years~* serum anti-HCV antibody (+)~* HCV RNA detectable by PCR~* compensated liver disease (Child-Pugh class A)~Exclusion Criteria: any of below~* HCV genotype other than 1, 2, or 3~* acute hepatitis C~* decompensated cirrhosis or hepatocellular carcinoma~* other liver disease such as hepatitis A or B, or autoimmune hepatitis~* HIV Ab(+)~* severe depression or other psychiatric disease~* previous organ transplantation~* absolute neutrophil count (ANC) \< 1,000 cells/mm3 or platelet count \< 75,000 cells/mm3, or hemoglobin (Hb) \< 13 g/dL for men, \<12 g/dL for women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Korean CHC (Type: EXPERIMENTAL): Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Myelodysplastic syndrome (de novo or secondary) fitting any of the recognized French-American-British classifications: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia with white blood cells less than 13,000 /mm3~* International Prognostic Scoring System (IPSS) greater than or equal to 0.5 (Intermediate-1, Intermediate-2 or high risk) by bone marrow assessment and bone marrow cytogenetics within 28 days before study registration~* 20 years or older~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Normal renal and hepatic function~Exclusion Criteria:~* Acute Myeloid Leukemia (AML) with bone marrow blasts greater than or equal to 30%~* Participants with a history of high-dose cytarabine (Ara-C) therapy (greater than 1,000 mg/m2/day)~* Participants administered adrenal cortex hormones or anabolic hormones within 7 days of study initiation~* Participants who have received a colony stimulating factor (CSF) formulation within 7 days of study initiation~* Active double cancer~* Uncontrolled cardiac disease or cognitive heart failure~* Uncontrolled restrictive or obstructive pulmonary disease~* Uncontrolled diabetes mellitus~* Active viral or bacterial infection~* Known positive serology for Human immunodeficiency virus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: JNJ-30979754 15 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
- Phase I: JNJ-30979754 20 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
- Phase II: JNJ-30979754 20 mg/m2 (Type: EXPERIMENTAL): JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Auto-immunity in Lupus Patients After Influenza Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* 18 years of age and older~* informed consent signed~* LES patients who meet the American College of Rheumatology (ACR) diagnostic criteria of SLE~* Patient able to attend all visit schedule during the month following influenza vaccine administration~* Clinical examination performed prior final inclusion with results communicated to the patient~Exclusion criteria :~* For women, being pregnant or positive pregnancy test~* Positive for HCV, HIV and HBV~* Patient treated with rituximab (anti-CD20) or stopped for less than a year.~* Patient for whom a treatment majorization is suspected within the month following influenza vaccine administration.~* Hypersensitivity to active substances, eggs and to one of the vaccine components~* Other vaccinations within the last 30 days before the inclusion at J0~* Administration of blood products such as immunoglobulins within the last 90 days before J0~* Progressive cancer, cirrhoses~* Acute severe illness within the last 30 days before inclusion at J0~* Patient non affiliated to a health social security system~* Planned participation to another clinical study during the present study period~* patient deprived of freedom by an administrative or court order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine group (Type: EXPERIMENTAL): single group: all included patients will receive the vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Comparison of Sildenafil ODF and FCT Formulations in Healthy Korean Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects were healthy male volunteers between the ages of 20 and 50 years and within 20% of their ideal body weight, and~* With no congenital abnormality or chronic disease.~Exclusion Criteria:~Key exclusion criteria included:~* history of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic, or hemorrhagic disease;~* anatomical abnormality of penis or factors that cause priapism (e.g., sicklemia, multiple myeloma, leukemia);~* clinically significant findings on routine laboratory (serology, hematology, serum chemistry, and urinalysis), ECG or color blindness tests \[8, 16\];~* history of hypersensitivity reaction to PDE5 inhibitor including sildenafil;~* use of prescription drugs within 14 days before the study that had the potential to interact with the study medication; and~* use of any substance that could induce or inhibit cytochrome P450 3A4 synthesis (eg, St. John's wort, other herbal medications).

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- SPO1101 (Type: EXPERIMENTAL): None
- SPO1101D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic spinal cord injury within 3 months prior to inclusion~* Neurogenic bladder dysfunction requiring intermittent catheterization at least 3 times daily~Exclusion Criteria:~* Has symptoms of UTI at inclusion~* Treated with prophylactic antibiotics to prevent UTIs~* Has a history of unresolved bladder-ureteral reflux and/or stones in the urinary tract~* Has used intermittent catheterization for more than 10 days prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SpeediCath (Type: EXPERIMENTAL): hydrophilic-coated intermittent catheter
- Conveen Uncoated (Type: EXPERIMENTAL): uncoated urinary intermittent catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~Exclusion Criteria:~* Use of any medication or anti-oxidant vitamin supplements.~* History of allergic reaction to atazanavir.~* Smoking.~* Previous spontaneous vagal collapse.~* History, signs or symptoms of cardiovascular disease.~* (Family) history of myocardial infarction or stroke under the age of 65 years.~* Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.~* Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90).~* Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50).~* Renal impairment (defined as plasma creatinin \>120 μmol/l).~* Liver enzyme abnormalities or positive hepatitis serology.~* Subjects with a total bilirubin level above 15 μmol/L and a normal direct bilirubin level suggesting Gilbert Syndrome.~* Positive HIV serology or any other obvious disease associated with immune deficiency.~* Febrile illness in the week before the LPS challenge.~* Participation in a drug trial or donation of blood 3 months prior to the LPS challenge.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
- Atazanavir (Type: ACTIVE_COMPARATOR): Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive~* On stable HAART regimen for at least 6 months prior to study entry~* T-cell count greater than 100 and viral load less than 1,000 for at least 6 months prior to study entry~* Fasting triglyceride level greater than 150 mg/dl~* Body mass index (BMI) greater than 18.5 and less than 30~* Uses barrier contraception~Exclusion Criteria:~* Fasting triglyceride level greater than 1000 mg/dl~* BMI less than 18.5 or greater than 30~* Taking diabetic medication or HbA1c less than 7.0~* Use of lipid lowering medication in the 30 days prior to study entry~* Unable to exercise~* T-cell count less than 100~* Current medical condition that makes exercise unadvisable~* History of coronary artery disease (CAD)~* Use of dietary supplements (within 30 days of study entry) that may affect lipid levels including, but not limited to, the following:~  1. Omega-3 fatty acids~ 2. L-Carnitine~ 3. Soluble fiber supplements~ 4. Guggul~ 5. Garlic supplements~ 6. Niacin greater than 25mg/d~ 7. Oral liquid supplements~* Use of steroids, hormones, or testosterone (without diagnosis of hypogonadism, testosterone less than 300 ng/dl)~* Irregular periods~* Depo-Provera~* Hypo- or Hyperthyroidism~* Adrenal insufficiency~* Serum alanine or aspartate aminotransferase level greater than 3 times the upper limit of normal~* Alcohol abuse~* Renal insufficiency (creatinine level greater than 1.5 mg/dl)~* Coumadin therapy~* Pregnancy~* Peptic ulcer disease~* Cholelithiasis~* History of hyperuricemia~* History of myositis or rhabdomyolysis~* Known adverse reaction to niacin or fibrates~* Hepatitis C therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Subjects receive lifestyle advice and placebos for Niaspan and Tricor
- 2 (Type: EXPERIMENTAL): Diet, exercise, and two placebos
- 3 (Type: EXPERIMENTAL): Diet, exercise, Niaspan, and placebo
- 4 (Type: EXPERIMENTAL): Diet, exercise, placebo, and Tricor
- 5 (Type: EXPERIMENTAL): Diet, exercise, Niaspan, and Tricor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Must be 6 to less than 18 years of age at the time of randomization~* Plaque-type psoriasis history for at least 3 months.~Severe plaque-type psoriasis meeting all of the following three criteria:~* PASI score of 20 or greater,~* Investigator's Global Assessment (IGA) score of 4~* Total body surface area (BSA) affected of 10% or greater.~* Patient being regarded by the investigator to be a candidate for systemic therapy because of:~  1. inadequate control of symptoms with topical treatment, or~ 2. failure to respond to or tolerate previous systemic treatment and/or UV therapy~Exclusion criteria~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate) at randomization.~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Secukinumab low dose (Type: EXPERIMENTAL): Secukinumab
- Secukinumab high dose (Type: EXPERIMENTAL): Secukinumab
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Etanercept Comparator (Type: ACTIVE_COMPARATOR): Etanercept

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* proven Crohn's disease~* Single or multiple draining perianal fistulas~Exclusion Criteria:~* Abscesses~* Infliximab, cyclosporine, tacrolimus and antibiotics for Crohn's disease within past 3 months~* active viral infection~* significate cardiovascular dysfunction~* Pregnancy, Lactation~* Surgical bowel resection to be expected within 6 months~* Positive stool culture for enteric pathogens~* Total parental nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Adalimumab
- 2 (Type: PLACEBO_COMPARATOR): ciprofloxacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with no medical, psychiatric or current sleep disorders.~* Subject must sign a written consent form.~Exclusion Criteria:~* Recent history of night shift work or jet lag.~* Prior experience sleeping in a sleep lab environment.~* History of sleep disorders.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Take orally 30 minutes prior to bedtime.
- 20 mg VEC-162 (Type: EXPERIMENTAL): 20 mg taken orally 30 minutes prior to bedtime.
- 50 mg VEC-162 (Type: EXPERIMENTAL): 50 mg taken orally 30 minutes prior to bedtime.
- 100 mg VEC-162 (Type: EXPERIMENTAL): 100 mg taken orally 30 minutes prior to bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed the 6-Month Treatment Period in pivotal study M12-671.~* Agrees to use required birth control methods during the study through Month 6 of the Post-treatment Follow-up period~Exclusion Criteria:~* Clinically significant gynecological condition~* Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine, femoral neck or total hip~* Plans to become pregnant in the next 18 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the criteria of ADHD (predominantly inattentive type \[314.00\], predominantly hyperactive-impulsive type \[314.01\], and combined type \[314.01\]) of DSM-IV-TR both at present and in childhood, based on Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID) at screening~* DSM-IV Total ADHD Symptoms scores (18 items) of CAARS-O: SV score of = 24 as determined by investigator or co-investigator at baseline~* Healthy on the basis of physical examination, medical history, vital signs, 12-lead ECG and clinical laboratory tests performed at screening~* Women of childbearing potential must have a negative urine pregnancy test at screening~* Patients (and their legally-acceptable representative if patients are 18 or 19 years of age) must have signed an informed consent form (ICF), indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.~Exclusion Criteria:~* Presence or history of co-morbid psychiatric diagnosis per DSM-IV-TR criteria of bipolar I disorder, schizophrenia, schizoaffective disorder, or severe obsessive compulsive disorders~* Presence of co-morbid psychiatric diagnosis per DSM-IV-TR criteria of pervasive developmental disorder (including autistic disorder or Asperger's disorder), suicidality, or any other diagnosis that in the judgment the investigator or co-investigator would exclude the patient from the study~* Presence of motor tics, history of Tourette's disorder, or family history of Tourette's disorder~* Known or suspected mental retardation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- JNS001 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crossover Trial of AD036 in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, between 25 to 65 years of age, inclusive, at the Screening Visit.~* AHI 10 to \<20, or AHI ≥20 if meets PSG criteria~Exclusion Criteria:~* History of narcolepsy.~* Clinically significant craniofacial malformation.~* Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control. A medication for these purposes is defined by dosage form, such that a combination antihypertensive medication is considered 1 medication~* CPAP should not be used for at least 2 weeks prior to first study PSG~* History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AD036 (Type: EXPERIMENTAL): AD036 oral capsule administered before sleep
- Atomoxetine (Type: ACTIVE_COMPARATOR): Atomoxetine oral capsule administered before sleep
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule administered before sleep

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete